EICHORCondition: HER2-positive Solid Tumors · HER2-positive Breast Cancer · HER2-positive Colorectal Cancer · Sponsor: Bolt Biotherapeutics, Inc.
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | — |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | — |
| The University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| START Midwest | Grand Rapids, Michigan, United States | — |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | — |
| Levine Cancer Institute | Charlotte, North Carolina, United States | — |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| South Texas Accelerated Research Therapeutics | San Antonio, Texas, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
| Institut Bergonie | Bordeaux, France | — |
+ 9 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04278144